期刊文献+

CD 40激发肿瘤抗原特异性DCs对CIK细胞生物学活性的影响 被引量:2

Effects of CD 40-pulsed tumor specific dendritic cells on biological activity of cytokine-induced killer cells
下载PDF
导出
摘要 目的:研究CD40激发凋亡肿瘤细胞致敏的树突状细胞(dendritic cells,DCs)对细胞因子诱导杀伤(cytokine-inducedkiller,CIK)细胞的细胞表型、增殖活性及细胞毒活性的影响。方法:常规方法从健康人外周血单个核细胞中诱导DCs和CIK细胞,采用凋亡肿瘤细胞负载DCs,并用或不用激发型CD40单克隆抗体(CD40mAb)激活DCs成熟;成熟DCs与同源的CIK细胞共育5d,分别获得DC40Ag-CIK细胞及DCAg-CIK细胞;观察细胞增殖活性;流式细胞仪检测细胞表型;酶联免疫吸附实验(enzyme-linked immunosorbent assays,ELISA)法检测细胞培养上清液中IFN-γ的含量;[3H]-TdR掺入法测定细胞杀伤活性。结果:凋亡肿瘤细胞负载激发可使DCs上调表达CD1a、CD80、CD86、CD83、HLR-DR,联合CD40mAb激发可进一步促进DCs成熟;培养至第14天时,DC40Ag-CIK细胞、DCAg-CIK细胞、CIK细胞分别扩增(18.2±1.7)倍、(15.0±1.2)倍、(9.3±1.8)倍;DC40Ag-CIK细胞中的CD3+CD56+比例较DCAg-CIK细胞和CIK细胞明显上调(P<0.05);DC40Ag-CIK细胞、DCAg-CIK细胞对A549杀伤活性强于CIK细胞(P<0.05),并且DC40Ag-CIK细胞强于DCAg-CIK细胞(P<0.05);CIK细胞、DCAg-CIK细胞、DC40Ag-CIK细胞培养上清液中IFN-γ的含量递增,分别为(1494.7±246.3)pg/mL、(2706.3±197.0)pg/mL、(3676.3±335.0)pg/mL。结论:与单独凋亡肿瘤细胞负载的DCs相比,CD40激发的凋亡肿瘤细胞负载的DCs可进一步提高CIK细胞的增殖活性及细胞毒活性。 Objective:To investigate the changes of phenotypes, proliferation activity and cytotoxicity of cytokine-induced killer (CIK) cells after co-cultured with autologous dendritic cells sensitized by CD 40-pulsed apoptotic tumor cells. Methods: DCs and CIK cells were induced from peripheral blood mononuclear cells (PBMC) of healthy subjects by the regular method. The immature DCs were loaded with apoptotic tumor cells pulsed with or without CD 40 mAb. The mature DCs were co-cultured with CIK cells for 5 d to obtain DC40Ag-CIK cells and DCAg-CIK cells. The proliferative activity of the effector cells was observed. Cell phenotypes were analyzed by flow cytometry. The level of interferon IFN-γ in the supematant of cultured cells was measured by enzyme-linked immunosorbent assays (ELISA). The cytotoxicity was detected by [^3 H] TdR incorporation method. Results :The expression rates of CD 1a, CD 80, CD 83, CD 86, and HLR-DR were up-regulated in DCs after loaded with apoptotic tumor cells. CD 40 mAb-pulsed apoptotic tumor cells further induced maturation of DCs. On the 14th day the DC40Ag-CIK cells, DCAg-CIK cells, and CIK cells proliferated and expanded ( 18.2 ± 1.7) times, ( 15.0 ± 1.2) times, (9.3 ±1.8) times, respectively. The proportion of CD3^+CD56^+ cells was markedly up-regulated in DC40Ag-CIK cells compared with DCAg-CIK cells and CIK cells (P 〈0.05 ). The cytotoxicity of DC40Ag-CIK cells and DCAg-CIK cells on A 549 cells was enhanced compared with CIK cells (P 〈0.05). DC40Ag-CIK cells had much stronger cytotoxicity than DCAg-CIK cells ( P 〈 0.05 ). The level of IFN-γ was ( 1494.7 ± 246.3 ) , ( 2706.3 ± 197.0) , and ( 3676.3 ± 335.0) pg/mL in the supernatant of CIK, DCAg-CIK, and DC40Ag-CIK cell cultures, respectively. Conclusion: DCs loaded with apoptotic tumor cells pulsed by CD 40 could further enhanced the proliferative activity and cytotoxicity of CIK cells compared with those without CD 40 pulsation.
出处 《肿瘤》 CAS CSCD 北大核心 2007年第12期953-956,共4页 Tumor
基金 江苏省社会发展基金科技项目(编号:BS200038) 江苏省高校自然科学基础研究项目(编号:06KJB320100)
关键词 抗原 肿瘤 树突细胞 细胞因子 杀伤细胞 细胞凋亡 抗原 CD40 Antigens,neoplasm Dendritic cells Cytokine Killer cells Apoptosis Antigens,CD 40
  • 相关文献

参考文献12

  • 1HUNTER T B, ALSARRAJ M, GLADVE R P, et al. An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-turnout T-cell responses in an in vitro mixed autologous turnout cell/lymph node cell model [ J ]. Scand J Immunol, 2007,65(5): 479-486.
  • 2ZHOU Z H, WANG J F, WANG Y D, et al. An agonist anti-human CD40 monoclonal antibody that induce dendritic cell formation and mature inhibits proliferation of a myeloma cell ine [ J ]. Hybridoma, 1999,18(6) :471-478.
  • 3黄建安,朱一蓓,古涛,席泓,王天立,戴俊,张学光.肺癌患者外周血树突状细胞的生物学特性研究[J].中国肿瘤生物治疗杂志,2003,10(3):175-179. 被引量:4
  • 4FENG H, ZENG Y, GRANER M W, et al. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells [ J]. Blood,2002,100(12) :4108-4115.
  • 5BLACHERE N E, DARNELL R B, ALBERT M L. Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation [J]. PLoS Biol,2005,3(6) : e185.
  • 6SIEVERS E, ALBERS P, SCHMIDT-WOLF IG, et al. Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma[J]. J Urol,2004,171(1) :114-119.
  • 7GONZALEZ-CARMONA M A, MARTEN A, HOFFMANN P, et al. Patient-derived dendritic cells transduced with an α-fetoproteinencoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells [ J ]. Liver Int, 2006, 26 (3) :369-379.
  • 8LINN Y C, HUI K M. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia [ J ]. Leukemia Lymphoma ,2003,44 (9) :1457-1462.
  • 9FUJII S, SHIMIZU K, KRONENBERG M, et al. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs[J]. Nat Immunol, 2002,3(9) :867-874.
  • 10TOMITA Y,BILIM V,HARA N,et al. Role of IRF-1 and caspase-7 in IFN-gamma enhancement of Fas-mediated apoptosis in ACHN renal cell carcinoma cells[J]. Int J Cancer, 2003,104 (4) :400- 408.

二级参考文献19

  • 1Schultze JL, Cardoso AA, Freeman G J, et al. Follicular lymphomas can be induced to present a.lloantigen efficiently: A Conceptual model to improve their tumor immunogenicity [ J]. Proc Natl Acad Sci USA, 1995, 92: 8200..8204.
  • 2Cardoso AA, Schultze JL, Boussiotis VA, et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen[J]. Blood, 1996t, 88: 41-48.
  • 3Restifo NP, Kawakami Y, Marlncola F, et al. Molecular mechanisms used by tumors to escape immune recognition: Immmunogenetherapy and the cell biology of major histocompatibility complex class I [J]. J Immuno Ther. 1993. 14: 182-190.
  • 4Khanna R, Cooper L, Kienzle N, et al. Engagement of CD40 antigen with soluble CIM01igand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells[J]. J Immunol, 1997. 159: 5782-6785.
  • 5Ridge JP, Rosa FD, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD +4 T-helper and a T killer cell[J]. Nature, 1998, 393: 474-478.
  • 6Jefford M, Maraskovsky E, Cebon J, et al. The use of dendritic cells in cancer therapy[J]. Lancet, 2001 : 343-353.
  • 7Saito H, Tsujitani S, Kondo A, et al. Combined analysis of tumor neoangiogenesis and local immune response in advanced gastric carcinoma[J]. Oncol Rep, 1999, 6: 459-463.
  • 8Ellem KA, Schmidt CW, Li CL, et al. The labyrinthine ways of cancer immunotherapy T cell, tumor cell encounter: "how do I lose thee? Let me count the ways" [J]. Adv cancer Res, 1998,75 : 203-249.
  • 9Steinbrink K, Wolfl M, Jonuleit H, et al. Induction of tolerance by IL-10-tw.ated dendritic cells[J]. J Immunol, 1997, 159:4772-4780.
  • 10Gabilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells[J]. Nat Med, 1996, 2: 1096-1103.

共引文献3

同被引文献22

  • 1ELGUTE R, BENSON M J, DE VRIES V C, et al. Molecular mechanism and function of Cd40/CD40L engagement in the immune system[ J ]. lmmunol Rev, 2009,229 ( 1 ) :152-172.
  • 2WU Y, WANG L, HE X, et al. Expression of CD40 and growth inhibitory activity of CD40 ligand in colon cancer ex vivo [ J ]. Cell Immunol, 2008,253 (1/2) :102-109.
  • 3VONDERHEIDE R H. Prospect of targeting the CD40 pathway for cancer therapy[ J]. Clin Cancer Res, 2007,13 (4) : 1083-1088.
  • 4BEREZNAYA N M, KIRNASOVSKAYA E A, VINNICHUK Y D, et al. Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors[ J]. Exp Oncol, 2008,30(4) :295-299.
  • 5HOLUB M,ZAKERI S M,LICHTENBERGER C,et al. Heterogeneous expression and regulation of CD40 in human hepatocellular carcinoma[ J]. Eur J Gastroenterol Hepatol, 2003,15 (2) : 119- 126.
  • 6SABEL M S, YAMADA M, KAWAGUCHI Y, et al. CD40 expression on human lung cancer correlates with metastatic spread [ J ]. Cancer lmmunol lmmunother, 2000,49 ( 2 ) : 101 - 108.
  • 7GAILAGHER N J, ELIOPOULOS A G, AGATHANGELO A, et al. CD40 activation in epithelial ovarian carcinoma ceils modulates growth, apoptosis, and cytokine secretion[ J]. Mol Pathol, 2002, 55(2) :110-120.
  • 8BUSSOLATI B, RUSSO S, DEAMBROSIS I, et al. Expression of CD154 on renal cell carcinomas and effect on cell proliferation, motility and platelet activating factor synthesis[J], lnt J Cancer, 2002,100(6) :654-661.
  • 9HIRSCHOWITZ E A,FOODY T,HIDALGO G E,et al.Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells[J].Lung Cancer,2007,57(3):365-372.
  • 10EUBEL J,ENK A H.Dendritic cell vaccination as a treatment modality for melanoma[J].Expert Rev Anticancer Ther,2009,9(11):1631-1642.

引证文献2

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部